scholarly journals 223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study

2020 ◽  
Vol 31 ◽  
pp. S330
Author(s):  
A.J. ten Tije ◽  
S. van Steenis ◽  
J. Briers ◽  
E.M.P. Elsten
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Final Analysis ◽  
Injection Device ◽  
Her2 Positive ◽  
Open Label ◽  
Phase Iiib ◽  
Open Label Phase ◽  
Single Use ◽  
At Home

scholarly journals Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

2020 ◽  
Vol 181 (1) ◽  
pp. 97-105 ◽  
Author(s):  
Hannelore Denys ◽  
Corina L. Martinez-Mena ◽  
Marc T. Martens ◽  
Randal G. D’Hondt ◽  
Marie-Pascale L. Graas ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Her2 Positive ◽  
Open Label ◽  
Phase Iiib ◽  
Home Administration ◽  
At Home

CP-103 Subcutaneous single-use injection device and intravenous formulations in patients with HER2-positive early breast cancer

2014 ◽  
Vol 21 (Suppl 1) ◽  
pp. A41.3-A42
Author(s):  
I Martin Nuñez ◽  
G Lopez-Vivanco ◽  
J Salvador ◽  
I Porras ◽  
C Ramirez
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Injection Device ◽  
Her2 Positive ◽  
Single Use

scholarly journals 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet ◽  
2019 ◽  
Vol 393 (10191) ◽  
pp. 2591-2598 ◽  
Author(s):  
Xavier Pivot ◽  
Gilles Romieu ◽  
Marc Debled ◽  
Jean-Yves Pierga ◽  
Pierre Kerbrat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Breast Cancer ◽  
Randomised Trial ◽  
Final Analysis ◽  
Open Label ◽  
Phase 3 ◽  
Adjuvant Trastuzumab ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document